Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTL0009936 in healthy subjects
NCT02291783Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Nov 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing HTL0009936 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events, Changes in Safety Lab parameters and 2 more. Started Nov 2013; status: completed.
02
Drugs
HTL0009936
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02291783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291783.